Condition
Oligometastatic Cancer
Total Trials
4
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 3 (1)
Trial Status
Not Yet Recruiting2
Active Not Recruiting1
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07635108Not ApplicableNot Yet Recruiting
MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)
NCT07481799Phase 3RecruitingPrimary
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases
NCT07426250Not Yet RecruitingPrimary
Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease
NCT03569241Phase 2Active Not Recruiting
PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases
Showing all 4 trials